SEC Comment Letter for X4 Pharmaceuticals, Inc (XFOR) (CIK 0001501697) (XFOR) — Jan 7, 2025
X4 Pharmaceuticals, Inc (XFOR) (CIK 0001501697)
Date: Jan. 7, 2025 · CIK: 0001501697 · Accession: 0000000000-25-000138
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-38295
Letter
January 7, 2025 Adam Mostafa Chief Financial Officer X4 Pharmaceuticals, Inc 61 North Beacon Street, 4th Floor Boston, MA 02134 Re:X4 Pharmaceuticals, Inc Form 10-K for fiscal year ended December 31, 2023 Form 10-Q for the quarterly period ended September 30, 2024 File No. 001-38295 Dear Adam Mostafa: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
January 7, 2025
Adam Mostafa
Chief Financial Officer
X4 Pharmaceuticals, Inc
61 North Beacon Street, 4th Floor
Boston, MA 02134
Re:X4 Pharmaceuticals, Inc
Form 10-K for fiscal year ended December 31, 2023
Form 10-Q for the quarterly period ended September 30, 2024
File No. 001-38295
Dear Adam Mostafa:
We have completed our review of your filings. We remind you that the company and
its management are responsible for the accuracy and adequacy of their disclosures,
notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences